E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

Pharma-50-transparent_216px_red

Become a Fan

« PTAB Life Sciences Report -- Part I | Main | Novartis AG v. Torrent Pharmaceuticals Ltd. (Fed. Cir. 2017) »

April 18, 2017

Comments

I have to wonder - me being ever skeptical - if this "relaxation" has anything to do with the trend of weaker patents....

This is but the latest development in the FDA's strategy to expand its jurisdiction. In a perfect world, the company would sue the FDA for a declaratory judgement that it has no jurisdiction over the use of mouth swabs to determine potential health risks, and the court would curtail the agency's hyper-bureaucratic, cost ineffective, nanny state aggressiveness.

The comments to this entry are closed.

August 2017

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31